HRP20000738A2 - sPLA<->2<P> INHIBITOR ESTER - Google Patents

sPLA<->2<P> INHIBITOR ESTER Download PDF

Info

Publication number
HRP20000738A2
HRP20000738A2 HR20000738A HRP20000738A HRP20000738A2 HR P20000738 A2 HRP20000738 A2 HR P20000738A2 HR 20000738 A HR20000738 A HR 20000738A HR P20000738 A HRP20000738 A HR P20000738A HR P20000738 A2 HRP20000738 A2 HR P20000738A2
Authority
HR
Croatia
Prior art keywords
methyl
phenylmethyl
indol
acetic acid
oxy
Prior art date
Application number
HR20000738A
Other languages
English (en)
Croatian (hr)
Inventor
Michael Lyle Denney
John Michael Morin
Daniel Jon Sall
Jason Scott Sawyer
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of HRP20000738A2 publication Critical patent/HRP20000738A2/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/22Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an aralkyl radical attached to the ring nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HR20000738A 1998-05-01 1999-04-20 sPLA<->2<P> INHIBITOR ESTER HRP20000738A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8387398P 1998-05-01 1998-05-01
PCT/US1999/008538 WO1999056752A1 (en) 1998-05-01 1999-04-20 sPLA2 INHIBITOR ESTER

Publications (1)

Publication Number Publication Date
HRP20000738A2 true HRP20000738A2 (en) 2001-10-31

Family

ID=22181214

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20000738A HRP20000738A2 (en) 1998-05-01 1999-04-20 sPLA<->2<P> INHIBITOR ESTER

Country Status (22)

Country Link
EP (1) EP1073440B1 (https=)
JP (1) JP4459441B2 (https=)
KR (1) KR20010071197A (https=)
CN (1) CN1303290A (https=)
AT (1) ATE280155T1 (https=)
AU (1) AU755901B2 (https=)
BR (1) BR9910149A (https=)
CA (1) CA2331036A1 (https=)
DE (1) DE69921314T2 (https=)
EA (1) EA003277B1 (https=)
ES (1) ES2230847T3 (https=)
HR (1) HRP20000738A2 (https=)
HU (1) HUP0201636A1 (https=)
ID (1) ID27812A (https=)
IL (1) IL139203A0 (https=)
NO (1) NO315940B1 (https=)
NZ (1) NZ507391A (https=)
PL (1) PL344571A1 (https=)
SK (1) SK16332000A3 (https=)
TR (1) TR200003198T2 (https=)
WO (1) WO1999056752A1 (https=)
ZA (1) ZA200005561B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6140327A (en) * 1999-05-12 2000-10-31 Eli Lilly And Company Morpholino-n-ethyl ester derivative of an indole sPLA2 inhibitor
AU2252201A (en) * 1999-12-16 2001-06-25 Eli Lilly And Company Carbon monoxide-based synthesis of spla2 inhibitors
DE19962300A1 (de) * 1999-12-23 2001-06-28 Asta Medica Ag Substituierte N-Benzyl-Indol-3-yl-glyoxylsäure-Derivate mit Antitumorwirkung
EP1303262A2 (en) * 2000-07-14 2003-04-23 Eli Lilly And Company Use of a spla2 inhibitor for the treatment of sepsis
US8048880B2 (en) 2007-05-03 2011-11-01 Anthera Pharmaceuticals, Inc. Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase A2 (SPLA2) inhibitors and SPLA2 inhibitor combination therapies
CN101742907A (zh) * 2007-05-03 2010-06-16 安塞拉制药有限公司 采用分泌型磷脂酶a2(spla2)抑制剂和spla2抑制剂组合疗法治疗心血管疾病和血脂异常
US20150335498A1 (en) * 2014-05-22 2015-11-26 The Procter & Gamble Company Heterogenous mass containing foam
US10729600B2 (en) 2015-06-30 2020-08-04 The Procter & Gamble Company Absorbent structure
CA3004313A1 (en) 2015-11-04 2017-05-11 The Procter & Gamble Company Absorbent structure
US11173078B2 (en) 2015-11-04 2021-11-16 The Procter & Gamble Company Absorbent structure
EP3370664B1 (en) 2015-11-04 2022-01-26 The Procter & Gamble Company Absorbent article comprising an absorbent structure

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2036307C (en) * 1990-03-08 2002-07-09 Susan Jean Ward 3-arylcarbonyl-1-aminoalkyl-1h-indole-containing antiglaucoma compositions and method
BR9501404A (pt) * 1994-04-01 1996-03-05 Lilly Co Eli 1H-indol-3 glioxilamida e formulação farmacèutica
DE4435477A1 (de) * 1994-10-04 1996-04-11 Bayer Ag Cycloalkano-indol- und -azaindol-derivate
FI974437A7 (fi) * 1995-06-06 1997-12-05 Pfizer Substituoituja N-(indoli-2-karbonyyli)amideja ja johdannaisia glykogee nifosforylaasi-inhibiittoreina
JP2002542148A (ja) * 1998-12-21 2002-12-10 イーライ・リリー・アンド・カンパニー 敗血症の処置のための組み合わせ療法

Also Published As

Publication number Publication date
ATE280155T1 (de) 2004-11-15
EA003277B1 (ru) 2003-04-24
JP2002513761A (ja) 2002-05-14
PL344571A1 (en) 2001-11-05
KR20010071197A (ko) 2001-07-28
BR9910149A (pt) 2001-10-02
ZA200005561B (en) 2002-01-10
IL139203A0 (en) 2001-11-25
CN1303290A (zh) 2001-07-11
CA2331036A1 (en) 1999-11-11
ID27812A (id) 2001-04-26
DE69921314T2 (de) 2006-02-09
WO1999056752A1 (en) 1999-11-11
NO315940B1 (no) 2003-11-17
EP1073440B1 (en) 2004-10-20
AU3652599A (en) 1999-11-23
SK16332000A3 (sk) 2001-06-11
EP1073440A4 (en) 2002-07-17
HUP0201636A1 (en) 2002-09-28
NO20005477D0 (no) 2000-10-31
AU755901B2 (en) 2003-01-02
JP4459441B2 (ja) 2010-04-28
NO20005477L (no) 2000-10-31
DE69921314D1 (de) 2004-11-25
NZ507391A (en) 2003-12-19
TR200003198T2 (tr) 2001-03-21
ES2230847T3 (es) 2005-05-01
EP1073440A1 (en) 2001-02-07
EA200001141A1 (ru) 2001-04-23

Similar Documents

Publication Publication Date Title
ES2377223T3 (es) Éster metílico de ácido [[3-(2-amino-1,2-dioxoetil)-2-etil-1-(fenilmetil)-11H-indol-4-IL]oxi]acético como inhibidor de sPLA2
US5641800A (en) 1H-indole-1-functional sPLA2 inhibitors
US5684034A (en) 1H-indole-3-acetamide sPLA2 inhibitors
US5578634A (en) 1H-indole-3-acetic acid hydrazide sPLA2 inhibitors
HRP20000738A2 (en) sPLA&lt;-&gt;2&lt;P&gt; INHIBITOR ESTER
KR20120044350A (ko) 신규한 벤젠술폰아미드 화합물, 그의 합성 방법 및 의약 및 화장품에서의 그의 용도
EP1100492B1 (en) INDOLE sPLA2 INHIBITORS
EP1202963B1 (en) Spla2 inhibitors
US6274578B1 (en) sPLA2 inhibitor ester
EA002119B1 (ru) Способ получения 4-замещенных-1н-индол-3-глиоксамидов
US6140327A (en) Morpholino-n-ethyl ester derivative of an indole sPLA2 inhibitor
MXPA00010465A (en) sPLA2
CZ20004051A3 (cs) Ester jako inhibitor sPLA2
WO2004007450A1 (ja) 新規インドリン化合物およびその医薬用途

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
OBST Application withdrawn